Natpara quick start form 2026

Get Form
natpara label Preview on Page 1

Here's how it works

01. Edit your natpara label online
Type text, add images, blackout confidential details, add comments, highlights and more.
02. Sign it in a few clicks
Draw your signature, type it, upload its image, or use your mobile device as a signature pad.
03. Share your form with others
Send it via email, link, or fax. You can also download it, export it or print it out.

How to use or fill out natpara quick start form with our platform

Form edit decoration
9.5
Ease of Setup
DocHub User Ratings on G2
9.0
Ease of Use
DocHub User Ratings on G2
  1. Click ‘Get Form’ to open the natpara quick start form in the editor.
  2. Begin by filling out the Prescribing Physician Information section. Enter the physician's first and last name, along with their specialty.
  3. Next, move to the Patient Information section. Provide details such as the National Provider ID, patient’s full name, address, contact numbers, and date of birth.
  4. In the NATPARA Prescription section, select the strength of NATPARA required and specify dosing instructions. Ensure you indicate whether it is subcutaneous injection and quantity needed.
  5. Complete any Special Instructions or Precautions if applicable. This ensures that all necessary information is conveyed for safe administration.
  6. Finally, obtain signatures from both the prescriber and patient (or guardian) in the designated areas to authorize prescription and health information sharing.

Start using our platform today for free to streamline your document editing and form completion!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.
Contact us
Natpara Generic Name Formulations Parathyroid hormone (recombinant) 25mcg, 50mcg, 75mcg, 100mcg; lyophilized pwd for SC inj after reconstitution.
Takeda Issues US Recall of NATPARA (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate announced on September 6, 2019, and Takeda Provides NATPARA U.S. Regulatory Update announced on March 22, 2022.
The pharmaceutical company was unable to resolve manufacturing problems that led to a U.S. recall of the drug in 2019. Takeda will stop manufacturing its medication Natpara for a rare endocrine condition at the end of 2024 after failing to resolve longstanding production issues.
NATPARA is available as an injection (shot). You will need to inject NATPARA once a day directly under the skin of the thigh. Be sure to inject a different thigh (alternate thigh) every day.
October 4, 2022 Today, Takeda announced the discontinuation of Natpara at the end of 2024. The notice can be found here.

Security and compliance

At DocHub, your data security is our priority. We follow HIPAA, SOC2, GDPR, and other standards, so you can work on your documents with confidence.

Learn more
ccpa2
pci-dss
gdpr-compliance
hipaa
soc-compliance

People also ask

As follow up to our October 2022 communications, the purpose of this email is to remind you that Takeda will discontinue global manufacturing of NATPARA (parathyroid hormone) for Injection at the end of December 2024.

Related links